Comments Rhythm Pharmaceuticals (RYTM) on Friday said it expects net product revenues from global sales of IMCIVREE to be about $57 million for the fourth quarter of 2025, an increase of 11% on a sequential basis from the third quarter of 2025. Post navigation uniQure gains as FDA sets up meeting on gene therapyNew Partnership Between PureWay and PPSWG Aims to Transform How America Manages Pharmaceutical Waste
